Erratum to: "Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice"

Thibaud Sefiane,[1*] Geneviève McCluskey,[1*] Marie Clavel,[2] Hortense Maynadié,[1,3] Ivan Peyron,[1] Tovo David,[4] Camille Brochier,[5] François Saller,[1] Mariem Khamari,[1] Cécile V. Denis,[1,6] Olivier D. Christophe,[1] Peter J. Lenting,[1] Vincent Muczynski[1,7#] and Caterina Casari[1#]

[1]Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Hémostase Inflammation Thrombose U1176, 94276, Le Kremlin-Bicêtre, France; [2]Inovarion, Paris, France; [3]Centre de Référence Hémophilie, Hôpital Bicetre, AP-HP, Université Paris-Saclay, Le Kremlin-Bicetre, France; [4]F. Hoffmann-La Roche Ltd., Basel, Basel-Stadt, Switzerland; [5]Institut Roche, Boulogne-Billancourt, France; [6]Centre Hospitalier Régional Universitaire Nancy, Vandoeuvre-de-Nancy, France and [7]University College London – Cancer Institute, London, UK

**TS and GMC contributed equally as first authors.*
#VM and CC contributed equally as senior authors.

Correspondence: P.J. Lenting
peter.lenting@inserm.fr

Received: September 5, 2025.
Accepted: September 5, 2025.

https://doi.org/10.3324/haematol.2025.289135

During the processing of our article published in the September issue of Haematologica,[1] panels A and B in Figure 4 were unfortunately replaced by those of Figure 3A and 3B. We deeply apologize for this mistake and regret any inconvenience this may have caused. The correct panels A and B for Figure 4 are shown below.



Figure 4. Tail artery transection model. (A) Factor VIII (FVIII)-deficient mice were given intravenously vehicle, various doses of FVIII (2.5, 5, and 10 IU/kg), emicizumab (5 mg/kg) or sequence-identical analog of marstacimab (SIA-marstacimab) (1 mg/kg). Estimated plasma concentrations at time of injury were 5 IU/dL FVIII, 10 IU/dL FVIII, 20 IU/dL FVIII, 55 µg/mL emicizumab or 16 µg/mL SIA-marstacimab. Wild-type (WT) mice were used as control. If mice were not bleeding at 15 minutes (min), clots were dislodged. Mice were monitored for 30 min. During the 30-min observation time, periods of bleeding and bleeding arrest were noted. Bleeding patterns of 4 mice representative for each group are presented. For FVIII-treated mice, data for mice receiving the two lowest doses are depicted. (B) Blood loss for each individual mouse included in the study.

References

1. T. Sefiane, G McCluskey, M Clavel, et al. Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice. Haematologica 2025;110(9):2064-2075.